Multikinase Inhibitor Treatment in Thyroid Cancer

Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) therapy. Unfortunately, some thyroid cancer types are resistant to surgical and RAI therapy. Multikinase inhibitors (MKIs) can be used in the treatment of advanced refractory thyroid cancers. The objective of this review is to give an update on MKI treatment (lenvatinib, sorafenib, sunitinib, cabozantinib, pazopanib, vandetanib) of thyroid cancer, regarding its efficacy and safety profile. We evaluated 212 articles through a PubMed search. A total of 20 articles met the inclusion and none the exclusion criteria. The studies showed promising progression-free survival rates compared to placebo treatment from earlier studies and similar or better results compared to the SELECT and DECISION trials. Adverse effects (AEs) are substantial in the treatment with MKIs. Almost all patients treated with these novel drugs experienced AEs. It is therefore crucial to focus on the management of AEs for a decent long-term outcome. The AEs are often more severe in patients with high efficacy of MKIs, which could indicate a correlation. Taken together, the novel therapeutic regimen with MKIs has shown favorable results in otherwise treatment-resistant thyroid cancer.

[1]  KimWon Gu,et al.  Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study. , 2018 .

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  F. Frasca,et al.  Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors , 2013, Journal of cancer epidemiology.

[4]  M. Brose,et al.  Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. , 2019, European Journal of Cancer.

[5]  K. Shailubhai,et al.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs. , 2019, Journal of clinical and experimental hepatology.

[6]  G. Rinaldi,et al.  Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. , 2019, European journal of cancer.

[7]  M. Miccoli,et al.  Sunitinib in the Treatment of Thyroid Cancer. , 2019, Current medicinal chemistry.

[8]  A. Maia,et al.  Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. , 2019, Endocrine-related cancer.

[9]  P DESAIVE,et al.  [Thyroid cancer]. , 1951, Revue medicale de Liege.

[10]  K. Nakano,et al.  A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. , 2019, Future oncology.

[11]  H. Iwasaki,et al.  Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer , 2019, Medicine.

[12]  M. Molina-Vega,et al.  Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice , 2018, Endocrine.

[13]  E. Migliore,et al.  Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice. , 2018, Anticancer research.

[14]  C. O'Neill,et al.  Standard and emerging therapies for metastatic differentiated thyroid cancer. , 2010, The oncologist.

[15]  M. Lacouture,et al.  Incidence and risk of hand–foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta‐analysis , 2016, Clinical and experimental dermatology.

[16]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[17]  F. Pitoia,et al.  The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer , 2019, Endocrine.

[18]  Baiyang Chen,et al.  Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis , 2019, Journal of Cancer.

[19]  Frank Stenner,et al.  Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program , 2018, Journal of Cancer.

[20]  M. Fishman,et al.  Experience with sorafenib and adverse event management. , 2011, Critical reviews in oncology/hematology.

[21]  M. Schlumberger,et al.  Treatment‐emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT) , 2018, Cancer.

[22]  T. Fukuhara,et al.  Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction , 2018, European Thyroid Journal.

[23]  Radiology,et al.  Clinical Cancer esearch cer Therapy : Clinical se II Study of Daily Sunitinib in FDG-PET – Positive , ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid R Functional Imaging Correlation , 2010 .

[24]  Lesley Seymour,et al.  RECIST — learning from the past to build the future , 2017, Nature Reviews Clinical Oncology.

[25]  T. Choueiri,et al.  Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. , 2019, The Lancet. Oncology.

[26]  H. Iwasaki,et al.  Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study. , 2018, Oncology letters.

[27]  M. Papotti,et al.  Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach , 2007, The American journal of surgical pathology.

[28]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[29]  J. Schellens,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing , 2017, Clinical Pharmacokinetics.

[30]  M. Cabanillas,et al.  Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. , 2019, Seminars in oncology.

[31]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[32]  E. Kebebew,et al.  Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. , 2013, Thyroid : official journal of the American Thyroid Association.

[33]  Y. Hwangbo,et al.  Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer. , 2019, Endocrine journal.

[34]  A. Toniato,et al.  Papillary Thyroid Carcinoma: Factors Influencing Recurrence and Survival , 2008, Annals of Surgical Oncology.

[35]  C. von Buchwald,et al.  Trends in thyroid cancer: Retrospective analysis of incidence and survival in Denmark 1980-2014. , 2018, Cancer epidemiology.

[36]  A. Gianoukakis,et al.  Prolonged duration of response in lenvatinib responders with thyroid cancer , 2018, Endocrine-related cancer.

[37]  D. Grimm,et al.  Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension , 2018, International journal of molecular sciences.

[38]  A. Miyauchi,et al.  Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer , 2019, Head & neck.

[39]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[40]  P. Miccoli,et al.  Sorafenib and Thyroid Cancer , 2013, BioDrugs.

[41]  D. Grimm,et al.  The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors , 2017, International journal of molecular sciences.

[42]  A. Bockisch,et al.  [Differentiated thyroid cancer]. , 2015, Der Internist.

[43]  E. Mezosi,et al.  First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis. , 2019, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[44]  Hang-Seok Chang,et al.  Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea , 2019, Front. Endocrinol..

[45]  D. Grimm,et al.  Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment , 2019, International journal of molecular sciences.

[46]  A. Popovtzer,et al.  Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. , 2019, Endocrine-related cancer.

[47]  Bruno Larrivée,et al.  Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.

[48]  H. Iwasaki,et al.  Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. , 2019, Oncology letters.

[49]  Napoleone Ferrara,et al.  Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.

[50]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[51]  D. Grimm,et al.  Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. , 2019, Current vascular pharmacology.

[52]  C. Tomoda,et al.  Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. , 2018, Endocrine journal.

[53]  Young In Park,et al.  Diagnosis and treatment of patients with thyroid cancer. , 2015, American health & drug benefits.

[54]  T. Wang,et al.  Tumor angiogenesis and anti-angiogenic gene therapy for cancer , 2018, Oncology letters.

[55]  N. Busaidy,et al.  Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer , 2017, Current opinion in oncology.

[56]  Lena Claesson-Welsh,et al.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.